Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease

Wang, G., Li, Y., Xiong, C., Benzinger, T. L. S., Gordon, B. A., Hassenstab, J., Aschenbrenner, A. J., McDade, E., Clifford, D. B., Libre‐Guerra, J. J., Shi, X., Mummery, C. J., van Dyck, C. H., Lah, J. J., Honig, L. S., Day, G., Ringman, J. M., Brooks, W. S., … Fox, N. C. (2024). Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer’s disease. Alzheimer’s & Dementia, 20(4), 2698–2706. Portico. https://doi.org/10.1002/alz.13735
Authors:
Guoqiao Wang
Yan Li
Johannes Levin
Tammie L.S. Benzinger
Brian A. Gordon
Jason Hassenstab
Andrew J. Aschenbrenner
Eric McDade
David B. Clifford
Jorge J. Libre‐Guerra
Xinyu Shi
Catherine J. Mummery
Christopher H. van Dyck
James J. Lah
Lawrence S. Honig
Gregory S. Day
John M. Ringman
William S. Brooks
Nick C. Fox
Kazushi Suzuki
Johannes Levin
Mathias Jucker
Paul Delmar
Tobias Bittner
Randall J. Bateman
Affiliated Authors:
Lawrence S. Honig
Author Keywords:
autosomal dominant alzheimer's disease
dominantly inherited alzheimer network
gantenerumab
latent class analysis
solanezumab
surrogate biomarker
Publication Type:
Article
Unique ID:
10.1002/alz.13735
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: